

# Jorge R Georgakopoulos

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9584465/publications.pdf>

Version: 2024-02-01

38  
papers

511  
citations

687363

13  
h-index

713466

21  
g-index

38  
all docs

38  
docs citations

38  
times ranked

643  
citing authors

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 1  | Incidence of COVID-19 in Patients With Chronic Idiopathic Urticaria and Asthma on Omalizumab: A Multicentre Retrospective Cohort Study. <i>Journal of Cutaneous Medicine and Surgery</i> , 2022, 26, 319-320.  | 1.2 | 12        |
| 2  | Incidence and prognosis of COVID-19 in patients with psoriasis on apremilast: a multicentre retrospective cohort study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, .  | 2.4 | 7         |
| 3  | Efficacy and Safety of Adalimumab and Infliximab for Noninfectious Uveitis. <i>Ophthalmology</i> , 2022, 129, 357-359.   | 5.2 | 3         |
| 4  | Prevalence and Characteristics of Dupilumab-Induced Ocular Surface Disease in Adults With Atopic Dermatitis. <i>Cornea</i> , 2022, 41, 1242-1247.  | 1.7 | 8         |
| 5  | A Systematic Review Characterizing Psoriatic Arthritis Onset and Exacerbation in Patients Receiving Biologic Therapy. <i>Journal of Cutaneous Medicine and Surgery</i> , 2022, , 120347542210885.  | 1.2 | 1         |
| 6  | A systematic review of vitiligo onset and exacerbation in patients receiving biologic therapy. <i>JAAD International</i> , 2021, 2, 37-39.   | 2.2 | 3         |
| 7  | Incidence and prognosis of COVID-19 in psoriasis patients on biologic therapy: a multicentre retrospective cohort study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e485-e487.  | 2.4 | 6         |
| 8  | Facial and neck erythema associated with dupilumab treatment: A systematic review. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1339-1347.  | 1.2 | 63        |
| 9  | Two-year efficacy, safety, and drug survival of dupilumab for atopic dermatitis: A real-world Canadian multicenter retrospective study. <i>JAAD International</i> , 2021, 4, 67-69.  | 2.2 | 12        |
| 10 | The Utility of IL-17 Inhibitors in Neutrophilic Dermatoses: A Systematic Review. <i>Journal of Cutaneous Medicine and Surgery</i> , 2021, , 120347542110453.   | 1.2 | 1         |
| 11 | Long-term dupilumab treatment for chronic refractory generalized prurigo nodularis: A retrospective cohort study. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 1049-1051.   | 1.2 | 14        |
| 12 | Treatment discontinuation and rate of disease transmission in psoriasis patients receiving biologic therapy during the COVID-19 pandemic: A Canadian multicenter retrospective study. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1212-1214.                                 | 1.2 | 19        |
| 13 | Impact of COVID-19 on Patient-Initiated Discontinuation of Omalizumab in Two Academic Hospital Clinics at the University of Toronto. <i>Journal of Cutaneous Medicine and Surgery</i> , 2020, 24, 534-535.   | 1.2 | 0         |
| 14 | Patient-Driven Discontinuation of Apremilast During the COVID-19 Pandemic in Two Canadian Academic Hospital Clinics and One Community Practice. <i>Journal of Cutaneous Medicine and Surgery</i> , 2020, 24, 418-419.  | 1.2 | 3         |
| 15 | Rate of Patient-Driven Biologic Treatment Discontinuation During the COVID-19 Pandemic in 2 Academic Hospital Clinics at the University of Toronto. <i>Journal of Cutaneous Medicine and Surgery</i> , 2020, 24, 424-425.  | 1.2 | 7         |
| 16 | Patient-Driven Discontinuation of Dupilumab During the COVID-19 Pandemic in Two Academic Hospital Clinics at the University of Toronto. <i>Journal of Cutaneous Medicine and Surgery</i> , 2020, 24, 422-423.  | 1.2 | 12        |
| 17 | Comparative 12-week effectiveness and safety outcomes of biologic agents ustekinumab, secukinumab and ixekizumab for the treatment of plaque psoriasis: a real-world multicenter retrospective study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e416-e418. | 2.4 | 6         |
| 18 | Evaluation of long-term efficacy, safety, and reasons for discontinuation of dupilumab for moderate to severe atopic dermatitis in clinical practice: A retrospective cohort study. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 1530-1532.                                   | 1.2 | 23        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Short-Term Evaluation of the Real-World Efficacy and Safety of Dupilumab for the Treatment of Moderate-to-Severe Atopic Dermatitis: A Canadian Multicenter Retrospective Cohort Study. <i>Journal of Cutaneous Medicine and Surgery</i> , 2020, 24, 468-473.                 | 1.2 | 3         |
| 20 | Incidence of Conjunctivitis and Other Ocular Surface Disorders in Patients With Long-Term Dupilumab Use. <i>Journal of Cutaneous Medicine and Surgery</i> , 2020, 24, 527-528.   | 1.2 | 7         |
| 21 | Tofacitinib for the treatment of psoriasis and psoriatic arthritis. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2020, 155, 400-410.  | 0.8 | 9         |
| 22 | Biologic switching between interleukin 17A antagonists secukinumab and ixekizumab: a 12-week, multicenter, retrospective study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, e7-e8.   | 2.4 | 20        |
| 23 | Long-term 52-week trends in apremilast safety outcomes for treatment of psoriasis in clinical practice: a multicentre, retrospective case series. <i>British Journal of Dermatology</i> , 2019, 180, 211-212.  | 1.5 | 3         |
| 24 | Off-Label High-Dose Secukinumab for the Treatment of Moderate-to-Severe Psoriasis. <i>Journal of Cutaneous Medicine and Surgery</i> , 2019, 23, 391-393.   | 1.2 | 10        |
| 25 | Ixekizumab (Interleukin 17A Antagonist): 12-week Efficacy and Safety Outcomes in Real-world Clinical Practice. <i>Journal of Cutaneous Medicine and Surgery</i> , 2019, 23, 174-177.   | 1.2 | 18        |
| 26 | Secukinumab dose optimization in adult psoriasis patients: A retrospective, multicenter case series. <i>JAAD Case Reports</i> , 2018, 4, 310-313.  | 0.8 | 14        |
| 27 | Efficacy and Safety of Apremilast Monotherapy for Moderate to Severe Psoriasis: Retrospective Study. <i>Journal of Cutaneous Medicine and Surgery</i> , 2018, 22, 290-296.   | 1.2 | 21        |
| 28 | Drug survival of secukinumab in real-world plaque psoriasis patients: A 52-week, multicenter, retrospective study. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 1019-1020.  | 1.2 | 37        |
| 29 | Efficacy and safety of switching to ixekizumab in secukinumab nonresponders with plaque psoriasis: A multicenter retrospective study of interleukin 17A antagonist therapies. <i>Journal of the American Academy of Dermatology</i> , 2018, 79, 155-157.                     | 1.2 | 42        |
| 30 | Systemic Monotherapy Treatments for Generalized Pustular Psoriasis: A Systematic Review. <i>Journal of Cutaneous Medicine and Surgery</i> , 2018, 22, 591-601.   | 1.2 | 13        |
| 31 | Efficacy and safety of secukinumab in treating moderate to severe plaque psoriasis in two real-world Canadian dermatology clinics: a multicenter retrospective study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, e32-e34.             | 2.4 | 27        |
| 32 | A comparison of apremilast monotherapy and combination therapy for plaque psoriasis in clinical practice: A Canadian multicenter retrospective study. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 623-626.   | 1.2 | 25        |
| 33 | Short-term reasons for withdrawal and adverse events associated with apremilast therapy for psoriasis in real-world practice compared with in clinical trials: A multicenter retrospective study. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 801-803. | 1.2 | 27        |
| 34 | A case of rituximab-induced pyoderma gangrenosum. <i>JAAD Case Reports</i> , 2018, 4, 979-981.   | 0.8 | 11        |
| 35 | Maintenance of therapeutic response after 1-year of apremilast combination therapy compared with monotherapy for the treatment of plaque psoriasis: A multicenter, retrospective study. <i>Journal of the American Academy of Dermatology</i> , 2018, 79, 953-956.           | 1.2 | 10        |
| 36 | Patient-Centred Care When Treating Plaque Psoriasis With Secukinumab: Reasons for Discontinuing Treatment Outside of Randomized Controlled Trials. <i>Journal of Cutaneous Medicine and Surgery</i> , 2018, 22, 647-649.   | 1.2 | 0         |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 37 | AB0939 Off-label secukinumab dose escalation in the treatment of moderate-to-severe psoriasis: a multicenter, retrospective study. , 2018, , .     |     | 0         |
| 38 | Short- and Long-Term Management of an Acute Pustular Psoriasis Flare: A Case Report. Journal of Cutaneous Medicine and Surgery, 2017, 21, 452-456. | 1.2 | 14        |